相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Secular and Regional Trends among Pulmonary Arterial Hypertension Clinical Trial Participants
Jeff Min et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2022)
United States Pulmonary Hypertension Scientific Registry Baseline Characteristics
Jessica B. Badlam et al.
CHEST (2021)
Adipokines and Metabolic Regulators in Human and Experimental Pulmonary Arterial Hypertension
Aimilia Eirini Papathanasiou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Obesity in Pulmonary Arterial Hypertension The Pulmonary Hypertension Association Registry
Jeff Min et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2021)
Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: Statistical recommendations for conduct and planning
Richard D. Riley et al.
STATISTICS IN MEDICINE (2020)
Obesity, estrogens and adipose tissue dysfunction - implications for pulmonary arterial hypertension
Kirsty M. Mair et al.
PULMONARY CIRCULATION (2020)
Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension
Kirsty M. Mair et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Pulmonary Hypertension and Obesity: Focus on Adiponectin
Fabio Perrotta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Therapy for Pulmonary Arterial Hypertension in Adults Update of the CHEST Guideline and Expert Panel Report
James R. Klinger et al.
CHEST (2019)
The obesity paradox in pulmonary arterial hypertension: the Scottish perspective
Luke Lawson McLean et al.
ERJ OPEN RESEARCH (2019)
Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension
Jason Weatherald et al.
CHEST (2018)
Sildenafil attenuates hypoxic pulmonary remodelling by inhibiting bone marrow progenitor cells
Shirley Favre et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ
Danielle L. Burke et al.
STATISTICS IN MEDICINE (2017)
Relation Between Obesity and Survival in Patients Hospitalized for Pulmonary Arterial Hypertension (from a Nationwide Inpatient Sample Database 2003 to 2011)
Manyoo Agarwal et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension
Hossein-Ardeschir Ghofrani et al.
CHEST (2017)
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Olivier Sitbon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
N. Galie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Survival advantages of excess body mass index in patients with idiopathic pulmonary arterial hypertension
En-Ci Hu et al.
ACTA CARDIOLOGICA (2014)
Obesity-related pulmonary arterial hypertension in rats correlates with increased circulating inflammatory cytokines and lipids and with oxidant damage in the arterial wall but not with hypoxia
David C. Irwin et al.
PULMONARY CIRCULATION (2014)
Comorbid Conditions and Outcomes in Patients With Pulmonary Arterial Hypertension A REVEAL Registry Analysis
Abby D. Poms et al.
CHEST (2013)
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study) A Randomized Controlled Trial
Victor F. Tapson et al.
CHEST (2013)
Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension A Randomized, Controlled Trial
Zhi-Cheng Jing et al.
CIRCULATION (2013)
Relevant Issues in the Pathology and Pathobiology of Pulmonary Hypertension
Rubin M. Tuder et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Tomas Pulido et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The association between obesity, mortality and filling pressures in pulmonary hypertension patients; the obesity paradox
Barak Zafrir et al.
RESPIRATORY MEDICINE (2013)
Fat, fire and muscle - The role of adiponectin in pulmonary vascular inflammation and remodeling
Benjamin D. Medoff
PULMONARY PHARMACOLOGY & THERAPEUTICS (2013)
Evolving Epidemiology of Pulmonary Arterial Hypertension
Thenappan Thenappan et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension Results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland
Yi Ling et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Molecular pathogenesis of pulmonary arterial hypertension
Marlene Rabinovitch
JOURNAL OF CLINICAL INVESTIGATION (2012)
Statistical Analysis of Individual Participant Data Meta-Analyses: A Comparison of Methods and Recommendations for Practice
Gavin B. Stewart et al.
PLOS ONE (2012)
Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese Adults
Manjunath P. Pai
PHARMACOTHERAPY (2012)
Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension
Julio Sandoval et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2012)
Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials
Raymond L. Benza et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2011)
Pulmonary Arterial Hypertension Baseline Characteristics From the REVEAL Registry
David B. Badesch et al.
CHEST (2010)
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension A Randomized Controlled Clinical Trial
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Nazzareno Galie et al.
CIRCULATION (2008)
Prostacyclin therapies for the treatment of pulmonary arterial hypertension
M. Gomberg-Maitland et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension
M. R. Wilkins et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Endothelin receptor antagonists in pulmonary arterial hypertension
J. Dupuis et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-γ activation
Georg Hansmann et al.
CIRCULATION (2007)
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan
Robyn J. Barst et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Sitaxsentan therapy for pulmonary arterial hypertension
RJ Barst et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Inhaled iloprost for severe pulmonary hypertension
H Olschewski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension - A double-blind, randomized, placebo-controlled trial
G Simonneau et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
分享论文
